Patents by Inventor Michael Plewe

Michael Plewe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds for the treatment of arenavirus
    Patent number: 11352328
    Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: June 7, 2022
    Assignee: Arisan Therapeutics Inc.
    Inventors: Michael Plewe, Eric Brown, Vidyasagar Gantla, Gregory Henkel, Kenneth McCormack, Nadzeda V. Sokolova, Young-Jun Shin
  • ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION
    Publication number: 20200017514
    Abstract: Compounds of structural Formula I were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus, wherein, R1, R2, R3, X and Y are defined in the specification.
    Type: Application
    Filed: July 12, 2018
    Publication date: January 16, 2020
    Inventors: Michael Plewe, Eric Brown, Vidyasagar Gantla, Gregory Henkel, Kenneth McCormack, Nadezda Sokolova
  • 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS
    Publication number: 20080090801
    Abstract: The present invention is directed to novel 4-methylpyridopyrimidinone compounds of Formula (I), and to salts thereof, their synthesis, and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-K?).
    Type: Application
    Filed: September 13, 2007
    Publication date: April 17, 2008
    Inventors: Hengmiao Cheng, Dilip Bhumralkar, Klaus Dress, Jacqui Hoffman, Mary Johnson, Robert Kania, Phuong Le, Mitchell Nambu, Mason Pairish, Michael Plewe, Khanh Tran
  • Inhibitors of the Hiv Integrase Enzyme
    Publication number: 20070232644
    Abstract: The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions comprising compounds of formula (I), and their methods of use in treating HIV-infected mammals.
    Type: Application
    Filed: August 26, 2005
    Publication date: October 4, 2007
    Inventors: Klaus Dress, Jon Kuehler, Michael Plewe, Anle Yang, Junhu Zhang
  • INHIBITORS OF THE HIV INTEGRASE ENZYME
    Publication number: 20070099915
    Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
    Type: Application
    Filed: October 6, 2006
    Publication date: May 3, 2007
    Inventors: Klaus Dress, Ted Johnson, Michael Plewe, Steven Tanis, Huichun Zhu
  • HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE
    Publication number: 20070004768
    Abstract: Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.
    Type: Application
    Filed: September 6, 2006
    Publication date: January 4, 2007
    Inventors: Qiyue Hu, Atsuo Kuki, Michael Plewe, Dawn Nowlin, Hai Wang, Junhu Zhang
  • HIV integrase inhibitors, pharmaceutical compositions and methods for their use
    Publication number: 20060122211
    Abstract: Beta-carboline hydroxamic acid compounds represented by formula (I) are described. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase-mediated diseases and conditions.
    Type: Application
    Filed: October 14, 2005
    Publication date: June 8, 2006
    Inventors: Atsuo Kuki, Xinqiang Li, Michael Plewe, Hai Wang, Junhu Zhang
  • Inhibitors of the HIV integrase enzyme
    Publication number: 20050277661
    Abstract: The present invention is directed to compounds of formula (i), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
    Type: Application
    Filed: April 25, 2005
    Publication date: December 15, 2005
    Inventors: Klaus Dress, Qiyue Hu, Ted Johnson, Michael Plewe, Steven Tanis, Huichun Zhu, Junhu Zhang
  • Inhibitors of the HIV integrase enzyme
    Publication number: 20050277662
    Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.
    Type: Application
    Filed: April 25, 2005
    Publication date: December 15, 2005
    Inventors: Klaus Dress, Qiyue Hu, Ted Johnson, Michael Plewe, Steven Tanis, Hai Wang, Anle Yang, Chunfeng Yin, Junhu Zhang
  • Glucagon antagonists/inverse agonists
    Publication number: 20050203108
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: November 3, 2004
    Publication date: September 15, 2005
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Christensen, Behrend Lundt, Ulla Sidelmann, Henning Thogersen, Anthony Ling, Michael Plewe, Larry Truesdale, Anker Jogensen, Janos Kodra, Shenghua Shi
  • HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use
    Publication number: 20050165040
    Abstract: Beta-carboline hydroxamic acid compounds represented by formula (I) are described. The beta-carboline hydroxamic acid compounds and compositions containing those compounds may be used to inhibit or modulate the activity of HIV integrase enzyme and to treat HIV integrase-mediated diseases and conditions.
    Type: Application
    Filed: January 26, 2004
    Publication date: July 28, 2005
    Inventors: Atsuo Kuki, Xinqiang Li, Michael Plewe, Hai Wang, Junhu Zhang